Graham Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Graham Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$364K	Buy	170,899 +84,343	+97%	+$201K	0.01%	735
2025 Q4	$210K	Buy	86,556 +50,035	+137%	+$177K	0.01%	1025
2025 Q3	$138K	Sell	36,521 -35,499	-49%	-$104K	﹤0.01%	1129
2025 Q2	$179K	Buy	+72,020	New	+$139K	﹤0.01%	1143
2024 Q1	–	Sell	-85,818	Closed	-$241K	–	1064
2023 Q4	$241K	Buy	+85,818	New	+$201K	0.01%	789

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Graham Capital Management's BDTX Position: Q1 2026 in Review

Graham Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 97% in Q1 2026, buying an estimated $201K and bringing the position to 170,899 shares worth $364K. The position accounts for 0.01% of the portfolio, ranked #735.

Graham Capital Management first reported a position in BDTX in Q4 2023 and has held it in 5 quarters since. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Graham Capital Management held 170,899 shares of Black Diamond Therapeutics worth $364K as of Q1 2026.
Graham Capital Management bought 84,343 Black Diamond Therapeutics shares in Q1 2026, an estimated $201K.
Black Diamond Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #735 holding.
Graham Capital Management first reported a position in Black Diamond Therapeutics in Q4 2023 and has held it in 5 quarters since.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.